Liraglutide causes large and rapid epicardial fat reduction

Obesity

Volumn 25, Issue 2, 2017, Pages 311-316

  Iacobellis, Gianluca ^a   Mohseni, Mahshid ^a   Bianco, Suzy D ^a   Banga, Pritisheel K ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; LIRAGLUTIDE; METFORMIN; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLYCOSYLATED HEMOGLOBIN;

ADULT; ARTICLE; BLOATING; BODY MASS; CARDIOMETABOLIC RISK; CONSTIPATION; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG EFFICACY; DRUG SAFETY; EPICARDIAL FAT; EPICARDIAL FAT TISSUE REDUCTION; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; INTERVENTION STUDY; INTRAPERITONEAL FAT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OPEN STUDY; PATIENT COUNSELING; PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; REPRODUCIBILITY; TREATMENT DURATION; TREATMENT WITHDRAWAL; WEIGHT LOSS PROGRAM; WEIGHT REDUCTION; ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; DRUG EFFECTS; INTRA-ABDOMINAL FAT; METABOLISM; MIDDLE AGED; PERICARDIUM; RISK FACTOR;

ADIPOSE TISSUE; ADULT; BODY MASS INDEX; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; INTRA-ABDOMINAL FAT; LIRAGLUTIDE; MALE; METFORMIN; MIDDLE AGED; PERICARDIUM; RISK FACTORS;

EID: 85010332827     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.21718     Document Type: Article

References (33)

1. Iacobellis G. Local and systemic effects of the multifaceted epicardial adipose tissue depot. Nat Rev Endocrinol 2015;11:363-371.
2. Iacobellis G, Bianco AC. Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features. Trends Endocrinol Metab 2011;22:450-457.
3. McAninch EA, Fonseca TL, Poggioli R, et al. Epicardial adipose tissue has a unique transcriptome that is downregulated in severe coronary artery disease. Obesity 2015;23:1267-1278.
4. Iacobellis G, Corradi D, Sharma AM. Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Nat Clin Pract Cardiovasc Med 2005;2:536-543.
5. Iacobellis G, Lonn E, Lamy A, Singh N, Sharma AM. Epicardial fat thickness and CAD correlate independently of obesity. Int J Cardiol 2011;146:452-454.
6. Mahabadi AA, Berg MH, Lehmann N, et al. Association of epicardial fat with cardiovascular risk factors and incident myocardial infarction in the general population: the Heinz Nixdorf Recall Study. J Am Coll Cardiol 2013;61:1388-1395.
7. Iacobellis G, Ribaudo MC, Zappaterreno A, Iannucci CV, Leonetti F. Relation between epicardial adipose tissue and left ventricular mass. Am J Cardiol 2004; 94:1084-1087.
8. Iacobellis G, Assael F, Ribaudo MC, et al. Epicardial fat from echocardiography: a new method for visceral adipose tissue prediction. Obesity Res 2003;11:304-310.
9. Iacobellis G, Willens HJ. Echocardiographic epicardial fat: a review of research and clinical applications. J Am Soc Echocardiogr 2009;22:1311-1319.
10. Iacobellis G, Ribaudo MC, Assael F, et al. Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. J Clin Endocrinol Metab 2003;88:5163-5168.
11. Malavazos AE, Di Leo G, Secchi F, et al. Relation of echocardiographic epicardial fat thickness and myocardial fat. Am J Cardiol 2010;105:1831-1835.
12. Pierdomenico SD, Pierdomenico AM, Cuccurullo F, Iacobellis G. Metaanalysis of the relation of echocardiographic epicardial adipose tissue thickness and the metabolic syndrome. Am J Cardiol 2012;15:1234-1236.
13. Iacobellis G. Epicardial fat: a new cardiovascular therapeutic target. Curr Opin Pharmacol 2016;27:13-18.
14. Lima-Martínez MM, Paoli M, Rodney M, et al. Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity: a pilot study. Endocrine 2016;51:448-455.
15. Grosso AF, de Oliveira SF, Higuchi Mde L, Favarato D, Dallan LA, da Luz PL. Synergistic anti-inflammatory effect: simvastatin and pioglitazone reduce inflammatory markers of plasma and epicardial adipose tissue of coronary patients with metabolic syndrome. Diabetol Metab Syndr 2014;6:47.
16. Alexopoulos N, Melek BH, Arepalli CD, et al. Effect of intensive versus moderate lipid-lowering therapy on epicardial adipose tissue in hyperlipidemic post-menopausal women: a substudy of the BELLES trial (Beyond Endorsed Lipid Lowering with EBT Scanning). J Am Coll Cardiol 2013;61:1956-1961.
17. Nauck M, Frid A, Hermansen K, et al., LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)−2 study. Diabetes Care 2009;32:84-90.
18. Marso SP, Daniels GH, Brown-Frandsen K, et al., LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-322.
19. Iacobellis G, Leonetti F. Epicardial adipose tissue and insulin resistance in obese subjects. J Clin Endocrinol Metab 2005; 90:6300-6302.
20. Sade LE, Eroglu S, Bozbaş H, et al. Relation between epicardial fat thickness and coronary flow reserve in women with chest pain and angiographically normal coronary arteries. Atherosclerosis 2009;204:580-585.
21. Mazurek T, Kochman J, Kobylecka M, et al. Inflammatory activity of pericoronary adipose tissue may affect plaque composition in patients with acute coronary syndrome without persistent ST-segment elevation: preliminary results. Kardiol Pol 2014;72:410-416.
22. Jendle J, Nauck MA, Matthews DR, et al., LEAD-2 and LEAD-3 Study Groups. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 2009;11:1163-1172.
23. Morano S, Romagnoli E, Filardi T, et al. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study. Acta Diabetol 2015;52:727-732.
24. Forst T, Michelson G, Ratter F, et al. Addition of liraglutide in patients with type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function. Diabet Med 2012;29:1115-1118.
25. Faber R, Zander M, Pena A, Michelsen MM, Mygind ND, Prescott E. Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes - a randomized, single-blinded, cross-over pilot study. Cardiovasc Diabetol 2015;14:41.
26. Chen WR, Hu SY, Chen YD, et al. Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J 2015;170:845-854.
27. Margulies KB, Hernandez AF, Redfield MM, et al., NHLBI Heart Failure Clinical Research Network. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 2016;316:500-508.
28. Vendrell J, El Bekay R, Peral B, et al. Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance. Endocrinology 2011;152:4072-4079.
29. Yang J, Ren J, Song J, et al. Glucagon-like peptide 1 regulates adipogenesis in 3T3-L1 preadipocytes. Int J Mol Med 2013;31:1429-1435.
30. Beiroa D, Imbernon M, Gallego R, et al. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Diabetes 2014; 63:3346-3358.
31. Aroor A, McKarns S, Nistala R, et al. DPP-4 inhibitors as therapeutic modulators of immune cell function and associated cardiovascular and renal insulin resistance in obesity and diabetes. Cardiorenal Med 2013;3:48-56.
32. Shah Z, Kampfrath T, Deiuliis JA, et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 2011;124:2338-2349.
33. Mazurek T, Opolski G. Pericoronary adipose tissue: a novel therapeutic target in obesity-related coronary atherosclerosis. J Am Coll Nutr 2015;34:244-254.